Public Policy

Lowenstein FDA Chair Eyes Biosimilar Battles, Off-Label Rules

Lowenstein Sandler LLP’s Jim Shehan, chair of the firm’s U.S. Food and Drug Administration practice, tells Law360 he's tracking patent litigation over biosimilars, watching for new off-label promotion policies and eyeing innovative approaches to clinical ...read more